Effects of mutant human Ki-rasG12C gene dosage on murine lung tumorigenesis and signaling to its downstream effectors

Toxicology and Applied Pharmacology

Volumn 231, Issue 1, 2008, Pages 77-84

  Dance Barnes, Stephanie T ^a   Kock, Nancy D ^a   Floyd, Heather S ^b   Moore, Joseph E ^a   Mosley, Libyadda J ^a   D'Agostino Jr , Ralph B ^a   Pettenati, Mark J ^a   Miller, Mark Steven ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TETRACYCLINE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE DOSAGE; GENE EXPRESSION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG ADENOMA; LUNG CARCINOGENESIS; MOUSE; MUTANT; NONHUMAN; ONCOGENE KI RAS; ONCOGENE RAS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA ANALYSIS; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR MODEL;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; GENE DOSAGE; GENES, RAS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSGENES;

MURINAE; MUS;

EID: 48449087330     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.04.014     Document Type: Article

References (42)

1. Agarwal M.L., Ramana C.V., Hamilton M., Taylor W.R., DePrimo S.E., Bean L.J., Agarwal A., Agarwal M.K., Wolfman A., and Stark G.R. Regulation of p53 expression by the RAS-MAP kinase pathway. Oncogene 20 (2001) 2527-2536
2. Alitalo K. Amplification of cellular oncogenes in cancer cells. Med. Biol. 62 (1984) 304-317
3. Bibbins K.B., Tsai J.Y., Schimenti J., Sarvetnick N., Zoghbi H.Y., Goodfellow P., and Silver L.M. Human homologs of two testes-expressed loci on mouse chromosome 17 map to opposite arms of chromosome 6. Genomics 5 (1989) 139-143
4. Bryan J.H. Spermatogenesis revisited. IV. Abnormal spermiogenesis in mice homozygous for another male-sterility-inducing mutation, hpy (hydrocephalic-polydactyl). Cell Tissue Res. 180 (1977) 187-201
5. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
6. Finney R.E., Robbins S.M., and Bishop J.M. Association of pRas and pRaf-1 in a complex correlates with activation of a signal transduction pathway. Curr. Biol. 3 (1993) 805-812
7. Floyd H.S., Farnsworth C.L., Kock N.D., Mizesko M.C., Little J.L., Dance S.T., Everitt J., Tichelaar J., Whitsett J.A., and Miller M.S. Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis 26 (2005) 2196-2206
8. Floyd H.S., Jennings-Gee J.E., Kock N.D., and Miller M.S. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol. Carcinog. 45 (2006) 506-517
9. Guo Y.L., Baysal K., Kang B., Yang L.J., and Williamson J.R. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J. Biol. Chem. 273 (1998) 4027-4034
10. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., and Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25 (1997) 151-157
11. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
12. Hayashida S., Harrod K.S., and Whitsett J.A. Regulation and function of CCSP during pulmonary Pseudomonas aeruginosa infection in vivo. Am. J. Physiol., Lung Cell. Mol. Physiol. 279 (2000) L452-L459
13. Horio Y., Chen A., Rice P., Roth J.A., Malkinson A.M., and Schrump D.S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol. Carcinog. 17 (1996) 217-223
14. Horn H.F., and Vousden K.H. Coping with stress: multiple ways to activate p53. Oncogene 26 (2007) 1306-1316
15. Howe L.R., Leevers S.J., Gomez N., Nakielny S., Cohen P., and Marshall C.J. Activation of the MAP kinase pathway by the protein kinase raf. Cell 71 (1992) 335-342
16. Jemal A., Cokkinides V.E., Shafey O., and Thun M.J. Lung cancer trends in young adults: an early indicator of progress in tobacco control (United States). Cancer Causes Control 14 (2003) 579-585
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J.Clin. 57 (2007) 43-66
18. Leone-Kabler S., Wessner L.L., McEntee M.F., D'Agostino Jr. R.B., and Miller M.S. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis 18 (1997) 1163-1168
19. Li Z.H., Zheng J., Weiss L.M., and Shibata D. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol. 144 (1994) 303-309
20. Malkinson A.M. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp. Lung Res. 24 (1998) 541-555
21. Massion P.P., Taflan P.M., Shyr Y., Rahman S.M., Yildiz P., Shakthour B., Edgerton M.E., Ninan M., Andersen J.J., and Gonzalez A.L. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit Care Med. 170 (2004) 1088-1094
22. Miller M.S. Tumor suppressor genes in rodent lung carcinogenesis-mutation of p53 does not appear to be an early lesion in lung tumor pathogenesis. Toxicol. Appl. Pharmacol. 156 (1999) 70-77
23. Mills N.E., Fishman C.L., Rom W.N., Dubin N., and Jacobson D.R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55 (1995) 1444-1447
24. Mitsudomi T., Viallet J., Mulshine J.L., Linnoila R.I., Minna J.D., and Gazdar A.F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6 (1991) 1353-1362
25. Mo L., Zheng X., Huang H.Y., Shapiro E., Lepor H., Cordon-Cardo C., Sun T.T., and Wu X.R. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J. Clin. Invest. 117 (2007) 314-325
26. Nikitin A.Y., Alcaraz A., Anver M.R., Bronson R.T., Cardiff R.D., Dixon D., Fraire A.E., Gabrielson E.W., Gunning W.T., Haines D.C., Kaufman M.H., Linnoila R.I., Maronpot R.R., Rabson A.S., Reddick R.L., Rehm S., Rozengurt N., Schuller H.M., Shmidt E.N., Travis W.D., Ward J.M., and Jacks T. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 64 (2004) 2307-2316
27. Pinkel D., Straume T., and Gray J.W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 2934-2938
28. Pu Q.Q., and Streuli C.H. Integrin control of cell cycle: a new role for ubiquitin ligase. BioEssays 24 (2002) 17-21
29. Pulciani S., Santos E., Long L.K., Sorrentino V., and Barbacid M. ras gene Amplification and malignant transformation. Mol. Cell. Biol. 5 (1985) 2836-2841
30. Reynolds S.H., Wiest J.S., Devereux T.R., Anderson M.W., and You M. Protooncogene activation in spontaneously occurring and chemically induced rodent and human lung tumors. Prog. Clin. Biol. Res. 376 (1992) 303-320
31. Ricketts M.H., and Levinson A.D. High-level expression of c-H-ras1 fails to fully transform rat-1 cells. Mol. Cell. Biol. 8 (1988) 1460-1468
32. Rodenhuis S. ras and human tumors. Semin. Cancer Biol. 3 (1992) 241-247
33. Serrano M. The tumor suppressor protein p16INK4a. Exp. Cell Res. 237 (1997) 7-13
34. Sewing A., Wiseman B., Lloyd A.C., and Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17 (1997) 5588-5597
35. Shockett P.E., and Schatz D.G. Diverse strategies for tetracycline-regulated inducible gene expression. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5173-5176
36. Slebos R.J., Hruban R.H., Dalesio O., Mooi W.J., Offerhaus G.J., and Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl. Cancer Inst. 83 (1991) 1024-1027
37. Tuveson D.A., and Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 18 (1999) 5318-5324
38. Umemura S., Itoh J., Itoh H., Serizawa A., Saito Y., Suzuki Y., Tokuda Y., Tajima T., and Osamura R.Y. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?. Appl. Immunohistochem. Mol. Morphol. 12 (2004) 8-13
39. Varmus H.E. The molecular genetics of cellular oncogenes. Annu. Rev. Genet. 18 (1984) 553-612
40. Westra W.H., Slebos R.J., Offerhaus G.J., Goodman S.N., Evers S.G., Kensler T.W., Askin F.B., Rodenhuis S., and Hruban R.H. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72 (1993) 432-438
41. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., and McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17 (1997) 5598-5611
42. Zhang Z., Wang Y., Vikis H.G., Johnson L., Liu G., Li J., Anderson M.W., Sills R.C., Hong H.L., Devereux T.R., Jacks T., Guan K.L., and You M. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29 (2001) 25-33